POCI · XBRL financial data

Precision Optics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (POCI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	10,675	15,678	21,044	19,104	19,091	31,532
Cost of revenue	7,241	10,750	13,310	13,307	15,687	—
Cost of goods and services sold	—	—	—	—	15,687	26,101
Gross profit	3,434	4,928	7,734	5,798	3,404	5,431
Research and development	624	666	992	982	1,158	1,033
Selling, general and administrative	3,715	5,613	7,380	7,540	7,798	7,907
Total operating expenses	4,339	6,442	8,373	8,522	8,956	8,940
Operating income (loss)	(906)	(1,514)	(639)	(2,724)	(5,551)	(3,509)
Interest expense	5	156	219	225	227	148
Income tax expense (benefit)	1	1	2	2	2	5
Net income (loss)	(103)	(928)	(145)	(2,951)	(5,780)	(3,630)
Earnings per share, basic USD per share	(0.01)	(0.06)	(0.03)	(0.49)	(0.85)	(0.43)
Earnings per share, diluted USD per share	(0.01)	(0.06)	(0.03)	(0.49)	(0.85)	(0.43)
Weighted average shares, basic thousands of shares	13,281	15,887	5,666	6,068	6,790	8,531
Weighted average shares, diluted thousands of shares	13,281	15,887	5,666	6,068	6,790	8,531

Fiscal years (POCI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	862	606	2,926	405	1,774	9,841
Accounts receivable	1,879	2,664	3,907	3,545	4,337	5,944
Inventory	1,885	3,022	2,776	2,868	3,562	3,829
Total current assets	4,776	6,505	9,859	7,118	10,058	20,109
Property and equipment, net	594	627	434	494	534	888
Right-of-use asset	61	518	358	190	142	2,301
Goodwill	688	8,824	8,824	8,824	8,824	8,824
Total assets	6,261	16,704	19,740	16,913	19,790	32,335
Accounts payable	1,205	2,239	2,432	1,397	2,909	3,583
Current portion of long-term debt	0	368	513	277	578	578
Total current liabilities	2,511	4,587	5,260	4,907	6,151	8,828
Long-term debt	0	1,961	2,176	1,899	1,289	711
Lease liability, non-current	0	367	190	12	91	2,447
Total liabilities	—	—	7,694	6,845	7,531	11,986
Accumulated deficit	(47,166)	(48,094)	(48,239)	(51,190)	(56,971)	(60,601)
Total stockholders' equity	3,431	8,971	12,047	10,068	12,259	20,349
Total liabilities and equity	6,261	16,704	19,740	16,913	19,790	32,335
Common shares outstanding (cover page) thousands of shares	13,282	16,915	6,067	6,350	7,715	10,973

Fiscal years (POCI's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(103)	(928)	(145)	(2,951)	(5,780)	(3,630)
Stock-based compensation	734	915	919	960	1,460	1,140
Depreciation and amortization	147	190	211	212	212	279
Net cash from operating activities	47	(933)	(81)	(2,683)	(3,547)	(1,550)
Purchases of property and equipment	76	113	17	272	227	427
Net cash from investing activities	(289)	(408)	(52)	(294)	(233)	(429)
Repayments of long-term debt	0	247	367	513	280	596
Net cash from financing activities	(31)	1,085	2,454	456	5,149	10,047

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.